Titan BiotechBOM:524717 -1.88%51 Net Margin % is 13.78% as of Mar. 2026, which is 2% below its 10-year median of 14.13. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹144.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Titan Biotech ranks better than 83.67% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Titan Biotech's Net Income for the
three
months ended in Mar. 2026 was ₹67 Mil. Titan Biotech's Revenue for the
three
months ended in Mar. 2026 was ₹488 Mil. Therefore, Titan Biotech's net margin for the quarter that ended in Mar. 2026 was 13.78%.
The historical rank and industry rank for Titan Biotech's Net Margin % or its related term are showing as below:
BOM:524717'
s Net Margin % Range Over the Past 10 Years
Min: 4.14 Med: 14.13 Max: 21.33
Current: 14.49
BOM:524717's Net Margin % is ranked better than 83.67% of 943
companies
in the Biotechnology industry
Industry Median: -89.33
vs BOM:524717: 14.49
Titan Biotech (BOM:524717) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Titan Biotech Net Margin % Related Terms
Titan Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Titan Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Net Margin % of 13.78% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Titan Biotech and its competitors. This is near median its historical median of 14.13. Over the past decade, Titan Biotech's Net Margin % has ranged from 4.14 to 21.33. According to the industry distribution chart, Titan Biotech ranks #154 out of 943 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Titan Biotech's Net Margin % too high?
Titan Biotech's current Net Margin % of 13.78% is near median its 10-year median of 14.13. Over the past 10 years, this metric has ranged from a low of 4.14 to a high of 21.33. Based on the distribution chart, Titan Biotech ranks #154 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #154 out of 943 companies for Net Margin %. This places Titan Biotech in the top 16% of its industry — outperforming the majority of peers. Historically, Titan Biotech's own Net Margin % has ranged from 4.14 to 21.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Titan Biotech and its competitors. Titan Biotech's current Net Margin % is 13.78%, which is near median its own 10-year median of 14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.21, compared to a current price of ₹390.40 — trading 170.7% above its estimated fair value. The current Net Margin % is 13.78%, which is near median its 10-year median of 14.13. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Net Margin % is 13.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹390.40 is trading 170.7% above its estimated GF Value™ of ₹144.21.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Net Margin %: 13.78% (near median its 10-year median of 14.13)
GF Value™: ₹144.21 vs. price of ₹390.40 (170.7% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
